Commitments

9 Months Ended

Sep. 30, 2016

Commitments.

Commitments

9. Commitments

In June 2015, we entered into a contract with a third party for clinical manufacturing supplies to support our ongoing clinical trials for ganaxolone.  Full delivery occurred during the first two quarters of 2016.  We recorded $3.0 million of research and development expense in the nine months ended September 30, 2016, all of which has been paid.